Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676099 | 0.85 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL586043 | 0.76 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3GPR119CYP2D6 | |
| SCHEMBL585821 | 0.76 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3GPR119CYP2D6 | |
| SCHEMBL586415 | 0.76 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3GPR119CYP2D6 | |
| SCHEMBL586162 | 0.75 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3GPR119CYP2D6 | |
| SCHEMBL585198 | 0.74 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3GPR119CYP2D6 | |
| SCHEMBL585767 | 0.74 | SLC6A2 (0.76) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2675874 | 0.73 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL585197 | 0.67 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3GPR119NNMT | |
| SCHEMBL585768 | 0.67 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417124-B1 | Serotonin and norepinephrine reuptake inhibitor | LILLY CO ELI (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | SLC6A2 1/4885SLC6A4 2/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.